



# YEAR IN REVIEW

# 2025



**GALV***med*

Protecting Livestock – Improving Human Lives

# Foreword

Small-scale livestock producers across sub-Saharan Africa continue to operate in an increasingly complex environment. Disease pressures remain high, climate variability is intensifying risk, and public animal health systems are often stretched beyond capacity. Yet livestock remains one of the most powerful and underused engines for improving livelihoods, food security and economic resilience.

GALVmed exists to address this gap. Our role is to innovate where markets fail: de-risking investment in the development of new and improved animal health products for low- and middle-income markets. Product innovation remains the foundation of our work, but innovation alone is not enough unless it translates into real-world use and impact. By developing sustainable market systems and strengthening regulatory pathways, we help ensure that innovative animal health solutions reach as many livestock producers as possible. We do this by working with the private sector, governments, regulators, development partners and others to correct persistent market and system failures that limit access to, and adoption of, quality animal health products by small-scale livestock producers.

2025 was a year of transition and momentum. PREVENT concluded after demonstrating, at unprecedented scale, that hatchery-based vaccination can be commercially viable and transformative for poultry producers. We believe this will fundamentally change how poultry vaccination is perceived and practised in multiple markets. GALVmed launched the second phase of our flagship programme, VITAL, building on almost two decades of experience in de-risking product development by intensifying our focus on product uptake, service delivery and last-mile impact in priority countries. This integrated approach links innovation with commercial delivery, regulatory systems strengthening and national vaccination priorities – ensuring that effective products reach livestock producers at scale.

This year also reinforced GALVmed's role as a trusted partner in regulatory and systems strengthening. From the expansion of the East African Community's Mutual Recognition Procedure to the endorsement of a pan-African network for veterinary product regulation, our work increasingly focuses on the enabling conditions that make long-term impact possible.

Across all our projects and programmes, a common theme is clear: sustainable progress depends on strong partnerships and well-functioning systems. None of the achievements described in this review would have been possible without the commitment of our partners – funders, researchers, manufacturers, governments, regulators, implementers and many others – who share our belief that well-functioning animal health markets are essential to development.

2025 also marks a leadership transition for GALVmed. I am honoured to take on the role of Chief Executive at a time when the organisation is well positioned for its next phase. I inherit an organisation with a strong reputation, a talented and committed team, and deep partnerships across Africa and beyond. My focus will be on building on this foundation: sharpening our strategic choices, strengthening delivery, and ensuring that GALVmed continues to play a distinctive and credible role in transforming the livelihoods of small-scale livestock producers in our target countries.

I would like to thank our partners and funders for their continued trust and collaboration, and the GALVmed team for their professionalism, dedication and growing presence in the countries where we work. Together, we are well placed to meet the challenges ahead and to unlock livestock's potential for small-scale livestock producers. These challenges are significant, but so too is the opportunity. With a strong foundation in innovation, market systems change and partnerships, we enter the next phase of our work with confidence, clarity of purpose and a shared commitment to improve the lives of small-scale livestock producers.

## **Dr Lois Muraguri**

Chief Executive, GALVmed





“

Across all our projects and programmes, a common theme is clear: sustainable progress depends on strong partnerships and well-functioning systems.

”

## GALVmed's flagship VITAL programme begins second phase

GALVmed's flagship programme, Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL), began its second five-year phase this year. Building on the preceding programme's development of innovative products, such as combination vaccines, and creation of largescale portfolio distribution networks in Africa and Asia, VITAL 2 will use private sector-driven initiatives to increase ruminant vaccination in sub-Saharan Africa, focusing on Kenya, Nigeria and Tanzania. In this way, the programme aims to transform the African ruminant vaccine market and improve the livelihoods of the small-scale livestock producers.

GALVmed officially launched VITAL 2 in Nigeria and Kenya at two high-profile events. In Nigeria, this was the Nigerian Veterinary Medical Association Congress, where more than 900 veterinary professionals and key stakeholders learned about the programme, with special emphasis on the veterinary service delivery component that is at the heart of VITAL 2's implementation. In Kenya, VITAL 2 was launched in Nairobi at a ruminant vaccination workshop co-convened with the Directorate of Veterinary Services and Kenya Veterinary Association. Over 80 participants – including representatives of national and county-level governments, the East African Community, regulators, the private sector

and development-sector organisations – gathered to align on national vaccination priorities and decide next steps.

VITAL 2 has since hit the ground running, and agreements with four commercial partners to implement ruminant vaccination in these countries have already been signed. These commercial partners have established in-country teams to support programme activities, and are now finalising distribution and partnership agreements to ensure a reliable supply of ruminant vaccines to the three countries. As working with national authorities and supporting their national vaccination programmes will be critical to VITAL 2's success, advocacy and engagement plans for Kenya, Nigeria and Tanzania have been developed and initial engagement with the public sector has been conducted. Thanks to this rapid deployment, products are already being registered as part of VITAL 2. By the end of 2025, 13 ruminant vaccines had been registered and 24 product dossiers had been submitted for registration in Kenya. In Tanzania, 12 ruminant vaccines had been registered and 9 product dossiers submitted. And in Nigeria, 3 ruminant vaccines had been registered while a further 27 product dossiers were submitted for registration.



VITAL 2’s commercial work is complimented by a research and development component that will create new technologies to combat specific livestock diseases. A partnership with the Pirbright Institute’s Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) will develop a safer and more effective Rift Valley Fever vaccine for use in low- and middle-income countries, particularly across Africa. CVIM will develop the vaccine, and GALVmed will work with the private sector to transfer the vaccine technology from CVIM, conduct safety and efficacy tests, including field trials, and secure market authorisation. Additionally, a partnership with the University of Toronto and the University of Calgary will see the development of a vaccine candidate for the control of haemorrhagic septicaemia in cattle.

The programme is also creating the necessary enabling environment for veterinary authorities to understand the benefits of private sector-delivered ruminant vaccine markets, with the ultimate aim of supporting the creation of public–private partnerships. GALVmed has begun an extensive landscaping exercise to map the areas where this advocacy work is most likely to achieve positive results.

GALVmed’s Monitoring and Evaluation (M&E) team have provided considerable support to the development of VITAL 2 this year, including creating the programme’s theory of change, results framework and key performance indicators. A comprehensive M&E plan sets out how VITAL 2 will collect, analyse and use data to evaluate both direct programme outcomes and how market functions and relationships change over time owing to VITAL 2’s work. The M&E team also produced a gender plan for VITAL 2 – developed with the International Livestock Research Institute (ILRI), the Gates Foundation, the Stanford Global Centre for Gender Equality, and Tanager – to integrate gender considerations into programme design, data collection and learning processes from the outset.



## VITAL 2

supports the creation of public–private partnerships to boost vaccination efforts



## RUMINANT VACCINES

registered under VITAL 2 across Kenya, Tanzania and Nigeria



## PRODUCT DOSSIERS

submitted for registration under VITAL 2



## PREVENT concludes after vaccinating more than 215 million day-old chicks

The final year of PREVENT (Promoting and Enabling Vaccination Efficiently, Now and Tomorrow) marked the successful completion of the project’s operational phase. Funded by the Gates Foundation and implemented by Ceva Santé Animale and GALVmed, PREVENT has introduced vaccination services to medium- and small-sized African hatcheries and promoted the use of pre-vaccinated poultry among small-scale producers, enhancing both productivity and sustainability in the poultry sector.

By the close of the four-year project in June 2025, a total of 48 hatcheries had been onboarded with 37 vaccinating – exceeding the original target of 36 – across 11 countries: Burkina Faso, Côte d’Ivoire, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Rwanda, Tanzania, Zambia and Zimbabwe. During 2025, 46.6 million day-old chicks were vaccinated as part of PREVENT, bringing the project’s cumulative total to more than 215 million vaccinated chicks over the life of the project. Vaccine administration also increased, with the 121 million doses given in 2025 bringing the overall total to nearly 581 million administered doses since PREVENT began in 2021.

The project trained more than 200 field technicians and established several technical mentorships strengthening hatchery performance and field-level vaccination practices. PREVENT’s M&E work this year, conducted with partners including Oxford Policy Management, ILRI and

SEBI-Livestock, included impact evaluation, field technician monitoring and modelling across several countries to assess the project’s additional impact. These studies, together with end-project data from Nigeria and Tanzania, provided valuable insights into gender dynamics, field-level implementation and the broader benefits of hatchery-based vaccination.

PREVENT concludes having successfully demonstrated that hatchery-based vaccination can be both commercially viable and transformative for poultry producers across sub-Saharan Africa and beyond. This accomplishment provides a strong foundation for continued collaboration between public and private partners to sustain and expand PREVENT’s innovative approach.



**VACCINE  
DOSES**

administered since  
PREVENT began in 2021



**HATCHERIES**

onboarded to PREVENT  
across 11 countries

## AgResults Foot and Mouth Disease Vaccine Challenge launches cost-share phase

One of the most infectious livestock diseases in the world, Foot and Mouth Disease (FMD) presents a constant threat to the global animal trade and national economies. In East Africa, where FMD is endemic, it can devastate livestock productivity and severely compromises small-scale livestock producers' livelihoods and food security. Vaccination is proven to effectively control FMD, but many livestock producers still lack access to a registered quadrivalent vaccine that could protect against all strains circulating in East Africa.

In response, the AgResults Foot and Mouth Disease Vaccine Challenge Project – an eight-year, \$17.34-million, pay-for-results competition – was launched in January 2020. Funded by AgResults (a collaboration between the Gates Foundation and the governments of Australia, Canada and the United Kingdom) and managed by GALVmed, the competition supports the development and uptake of high-quality quadrivalent FMD vaccines tailored to meet the needs of East Africa. In September 2024, the project celebrated the first-ever registration of just such a vaccine, developed by Moroccan vaccine manufacturer Biopharma.

To ensure registered vaccines are accessed and adopted by livestock producers, the project's Vaccine Distribution Cost-Share Phase began on 1 October 2024. This phase of the project funds a portion of the sale price of registered and approved vaccines. AgResults provides the cost-share funding to manufacturers on behalf of public- and private-sector buyers, enabling them to better combat FMD through improved access to more effective vaccines. The cost-share phase is already supporting the first buyers of Biopharma's FMD vaccine in the region.

In recognition of its pioneering work, this year the AgResults Vaccine Challenge won an FAO Global Recognition Award in the category of 'Sustainable Livestock Transformation, One Health, Animal Health and Reference Centres.' The project was one of just 50 initiatives to receive an award out of more than 400 applications from 72 countries.



### FUND

to support the creation of high-quality FMD vaccines for East Africa

## New project to boost disease surveillance in African hatchery laboratories

For laboratories with limited disease diagnosis and analysis capability, disease identification and surveillance is a lengthy and bureaucratic process, often requiring samples to be shipped overseas. In response, GALVmed has launched a three-year project, Enhancing Disease Surveillance for African Poultry (EDSAP). EDSAP will strengthen the diagnostic capacity of commercial hatchery laboratories in Ethiopia, Nigeria and Tanzania, expanding their current capabilities from serological analysis to include bacteriology and molecular biological analysis. This will help laboratories identify viral poultry diseases, such as new variants of avian influenza or infectious bursal disease. These private laboratories will not only help maintain product quality standards, but also provide poultry farmers with rapid disease diagnosis, treatment guidance and preventative support.

So far, partnerships have been established with EthioChicken in Ethiopia and Silverlands in Tanzania,

whose laboratories have been equipped to provide an expanded range of diagnostic services. To assess the impacts of this project, GALVmed's M&E team worked with Oxford Policy Management to design a system to track progress in laboratory capacity and disease surveillance. The system does this by monitoring essential upstream shifts – expanded test availability, faster turnaround times, increased sample submissions – that underpin better national responses to poultry disease outbreaks.



### NEWLY EQUIPPED LABORATORIES

provide a faster, expanded range of diagnostic services

## Pan-African network to strengthen veterinary medicine regulation is endorsed



Better Regulation is an ambitious three-year initiative to improve animal health and livestock production in sub-Saharan Africa. It does this by supporting countries to establish competent and sustainable national regulatory agencies to facilitate increased availability of quality veterinary medicines. One of Better Regulation's objectives is to establish an overarching governance structure for cooperation between national regulatory agencies responsible for veterinary medicines in sub-Saharan Africa. In 2025, GALVmed completed a comprehensive feasibility study for establishing this long-term governance structure.

Another major outcome of Better Regulation was a three-day consultative meeting in Nairobi on 17–19 November 2025. The meeting was organised by GALVmed in collaboration with the African Union Inter-African Bureau for Animal Resources (AU-IBAR) and the African Union Pan African Veterinary Vaccine Centre (AU-PANVAC), and in partnership

with Better Regulation's key partners, the World Organisation for Animal Health and UK Veterinary Medicines Directorate. At the gathering, attendees endorsed the creation of a pan-African network hosted by AU-IBAR, working closely with AU-PANVAC and the African Medicines Agency, to guide cooperation on veterinary product regulation.

The proposed Pan-African Regulatory Authorities Network for Veterinary Products will serve as a continental platform for veterinary product regulatory cooperation, helping countries align standards, share information and strengthen oversight of veterinary medicines. The network will also be mandated to develop harmonised regulatory guidelines, help national authorities build effective systems, and coordinate activities including quality control, surveillance and approval – decisions that are best handled collectively rather than by individual African Union member countries.



## Mutual Recognition Procedure continues to transform product registration in East Africa

The East Africa Community (EAC)'s Mutual Recognition Procedure (MRP) was established in 2014, with GALVmed's support, to harmonise animal health product registration across East Africa. Now in its eleventh year, the MRP continues to transform the system for registering veterinary products throughout the region. In 2025, 17 product applications were submitted and 5 products were registered under MRP.

This year also saw the development and review of several harmonised guidelines, some of which were launched in EAC countries. The Good Manufacturing Practice (GMP) Guideline – used by regulators to inspect the facilities of veterinary medicine manufacturers – was endorsed by the EAC's Sectoral Council of Agriculture Food and Security. Similarly, guidelines for Aquatic Animal Medicine Registration and for Animal Nutrient Registration, used to register medicines relating to aquatic animals and nutritional supplements respectively, were developed and endorsed by the EAC. A harmonised draft Regulatory Reliance Guideline was developed and will be reviewed by the MRP Technical Working Group in the first quarter of 2026.

Several capacity-strengthening activities were also conducted in 2025. The GMP Guideline was launched in all EAC countries, and the Aquatic Animal Medicine Registration Guideline in five EAC countries. GALVmed, working with expert consultants, also provided training to regulators on how to apply the guidelines in five

EAC countries. Training for the remaining countries is scheduled for January 2026. Senior assessors also received training on evaluating innovator products in 2025, delivered by regulatory experts from the Australia Veterinary Medicines and Pesticides Agency. This training focused on products derived from newly discovered molecules that have never been registered or used anywhere in the world, as well as vectored and combination vaccines, and GMP inspection of ectoparasiticide manufacturing facilities.

Currently, only four EAC countries fully participate in the MRP (Kenya, Rwanda, Tanzania and Uganda), with Burundi soon to join this list following the launch of its new regulatory agency, the Burundian Authority for the Regulation of Veterinary Products, Pesticides and Food. The Better Regulation project aims to have two additional EAC countries participating in MRP by the project's end in 2027. To this end, GALVmed is currently reviewing the veterinary medicines regulatory framework for South Sudan and the Federal Republic of Somalia. This will provide the groundwork for supporting the authorities to establish regulatory agencies in the two countries.



### PRODUCT APPLICATIONS

were submitted to the MRP in 2025

## GALVmed targets tick management in new Ugandan project

Initiated in 2024, MoTAR (Monitoring of Ticks and Acaricide Resistance) is a two-year project to provide Uganda with effective management of tick acaricide resistance (TAR) and the associated burden of tick-borne disease (TBD) – two major constraints on sustainable livestock production in the country.

The project, which is funded by the Gates Foundation, is being delivered by GALVmed through the Research Centre for Tropical Diseases and Vector Control at Makerere University. The project aims to create a network of laboratories that can provide TAR and TBD diagnostics, as well as TBD testing services, for affected regions of Uganda. Nine Ugandan laboratories have now

joined this surveillance network. This year, three of these laboratories were refurbished and upgraded as part of MoTAR, transforming them into leading research hubs with modern diagnostic equipment capable of mapping acaricide resistance, tick distribution and the prevalence of tick-borne pathogens.



### UGANDAN LABORATORIES

have joined a nationwide tick surveillance network

## GALVmed leads collaboration to improve access to Animal African Trypanosomiasis solutions



Animal African Trypanosomiasis continues to devastate livestock producers across sub-Saharan Africa, causing losses estimated at \$3 billion annually through reduced productivity, animal mortality and constrained livelihoods. This year, GALVmed convened a side meeting at the 37th International Scientific Council for Trypanosomiasis Research and Control Conference in Nairobi. This meeting brought together policymakers, researchers and industry partners to identify the barriers preventing new trypanocides from reaching small-scale livestock producers. GALVmed complemented these discussions with bilateral engagements with veterinary regulatory authorities in East Africa to improve the regulatory environment for trypanocides and to facilitate faster, safer access to existing and next-generation solutions.

GALVmed is also collaborating with key regional and international partners in Kenya and Uganda to strengthen regional capacity to evaluate new products and ensure that innovation translates into real-world impact. Through these and other alliances, GALVmed is facilitating the development of safer, more effective tools to overcome trypanocide resistance and ensure they reach the livestock producers who need them most.

## Monitoring and Evaluation implementing new systems to better capture GALVmed's impacts

In 2025, the M&E team provided essential support to many of GALVmed's projects and programmes, including VITAL 2, PREVENT, EDSAP and MoTAR. The focus of GALVmed's M&E has now shifted from framework design to active delivery of these and other projects, with a focus on implementing project evaluation systems. This will ensure that future reporting is founded on a coherent evidence base, enabling GALVmed to assess progress and systematic change across its diverse portfolio.

Our collaboration with SEBI-Livestock enabled us to develop dynamic production models for dairy and small ruminant systems, which will allow GALVmed to provide more accurate economic benefit and reach estimates. This work will continue into 2026 with the development of a pastoralist production model.

This year also saw the M&E team oversee an economic surplus analysis with ILRI. The approach was piloted using a Peste des Petits Ruminants vaccine case in India to quantify both the direct and wider benefits of vaccination. In parallel, the M&E team continued its work with the French Agricultural Research Centre for International Development on the Evaluation of Vaccination Strategies (EVACS) tool, which is used to assess vaccination coverage, immunity and spatial distribution. The EVACS study in Kenya, covering Contagious Bovine Pleuropneumonia, Lumpy Skin Disease and Rift Valley Fever, was extended to integrate additional national data sources, improving the robustness of results for future decision-making on vaccination strategies.

## GALVmed's governance receives clean bill of health for seventh consecutive year

GALVmed received a clean external audit report in 2025 for a seventh successive year, with no control weaknesses or suggestions for improvement identified.

This year also saw the organisation undergo a General Data Protection Regulation audit review and staff training. We also received Cyber Essentials certification again this year – confirming good data protection practices at GALVmed – and are currently working towards the more advanced Cyber Essentials Plus certification.

Another governance milestone was reached this year: for the first time in our history, GALVmed now employs more staff in the Global South than in our Head Office in Edinburgh. This shift reflects our ongoing commitment to increase our presence in the countries where we operate.



**SUCCESSIVE  
YEAR**

that GALVmed has received  
a clean external audit



**Head Office:**

Doherty Building,  
Pentlands Science Park,  
Bush Loan,  
Edinburgh,  
EH26 0PZ, UK

**Tel:** +44 (0) 131 445 6264

**Email:** [info@galvmed.org](mailto:info@galvmed.org)

**Website:** [www.galvmed.org](http://www.galvmed.org)

**Photos:**

Cover photo: FAO/Geroge Koranteng

Page 2: FAO/Lius Tato

Page 4: FAO/Tony Karumba

Page 5: GALVmed/Mediaproduct

Page 6: Colin Dames

Page 8: GALVmed

Page 9: ILRI/K Dhanji

Page 10: EADD

Back page: ILRI/Camille Hanotte



@galvmed



@GALVmed



@GALVmed



@galvmed



Protecting Livestock – Improving Human Lives

With funding from:



Gates Foundation